Enliven Therapeutics

CompanyUnited States

Enliven Therapeutics develops one asset, in phase 3 (relcobatinib in chronic myeloid leukemia). Mostly small molecule acting on BCR and ABL1; based in the United States.

1
Asset
Furthest: Phase 3; 1
Trial: 0
Signals

Pipeline

1

relcobatinib
Small molecule allosteric inhibitor of BCR-ABL1 tyrosine kinase
Phase 3, Small molecule, BCR, ABL1, chronic myeloid leukemia

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials1
Similar companies1

Updated 10 Oct 2026 · 3 sources